Beyond Air Inc (XAIR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Beyond Air Inc (XAIR) has a cash flow conversion efficiency ratio of -0.509x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.22 Million) by net assets ($8.29 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Beyond Air Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Beyond Air Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Beyond Air Inc for a breakdown of total debt and financial obligations.
Beyond Air Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Beyond Air Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cymat Technologies Ltd.
V:CYM
|
0.402x |
|
Albion Resources Ltd
AU:ALB
|
-0.617x |
|
Locafy Ltd
NASDAQ:LCFY
|
-0.096x |
|
ArcWest Exploration Inc
V:AWX
|
-0.006x |
|
Nippon Active Value Fund Plc
LSE:NAVF
|
0.009x |
|
Bio Green Med Solution, Inc.
NASDAQ:BGMS
|
-0.005x |
|
Can Fite Biopharma Ltd
TA:CANF
|
-0.425x |
|
Gulf Resources, Inc. (NV) Common Stock
NASDAQ:GURE
|
0.062x |
Annual Cash Flow Conversion Efficiency for Beyond Air Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Beyond Air Inc from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see XAIR market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $14.34 Million | $-38.22 Million | -2.665x | -29.34% |
| 2024-03-31 | $27.19 Million | $-56.02 Million | -2.060x | -162.34% |
| 2023-03-31 | $42.03 Million | $-33.01 Million | -0.785x | -165.52% |
| 2022-03-31 | $78.21 Million | $-23.13 Million | -0.296x | +54.12% |
| 2021-03-31 | $30.46 Million | $-19.64 Million | -0.645x | +23.23% |
| 2020-03-31 | $18.09 Million | $-15.19 Million | -0.840x | -352.02% |
| 2019-03-31 | $4.02 Million | $1.34 Million | 0.333x | +107.23% |
| 2018-03-31 | $1.54 Million | $-7.12 Million | -4.610x | -116.76% |
| 2017-03-31 | $-25.16K | $-692.00K | 27.504x | -58.26% |
| 2016-03-31 | $-25.16K | $-1.66 Million | 65.898x | +3679.61% |
| 2015-03-31 | $-1.08 Million | $-1.88 Million | 1.744x | -49.69% |
| 2014-03-31 | $-232.00K | $-804.00K | 3.466x | -- |
About Beyond Air Inc
Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treat… Read more